AcuCort AB (publ) (Spotlight Stock Market: ACUC), a Sweden-based biotechnology company, announced on Wednesday that it has signed an exclusive commercial agreement with Kamada Ltd., (NASDAQ: KMDA; TASE: KMDA.TA), an Israel-based global biopharmaceutical company.
The contract grants Kamada exclusive Israeli market rights to the marketing, sales and distribution of AcuCort's drug Zeqmelit for, among other things, treatment of acute allergy.
According to the terms of the contract, Kamada will be responsible for commercialisation of Zeqmelit in Israel and will have the exclusive right to marketing, sales, and distribution of the drug in this market. It is mandatory on Kamada to register Zeqmelit in Israel. Kamada's evaluation is that it will be able to implement for registration and market approval to the Israeli authority MOH, Ministry of Health, during the first quarter of 2023. The processing of the submitted application is likely to take place between 8 to 24 months.
Blacksmith Medicines granted US patent for antibacterial compounds targeting LpxC
Alvotech reports positive topline results for Xolair biosimilar study
DBV Technologies secures up to USD306.9m to advance Viaskin peanut patch programme
Health Canada approves ALK's ACARIZAX for young children with dust mite allergy
Allergy Therapeutics publishes positive Phase III data for Grass MATA MPL
CSL's ANDEMBRY receives European approval to prevent attacks of hereditary angioedema
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
European Commission approves Palforzia for toddlers with peanut allergy
Eli Lilly and Co receives approval from FDA for Zepbound
CSL gains EMA backing for Garadacimab as HAE prophylactic treatment
Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir)
Allergy Therapeutics reports positive data from VLP Peanut PROTECT trial
CBC Group acquires UCB's mature neurology and allergy business in China